PFIZER INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer
Phase 3
Completed
- Conditions
- Colorectal Cancer
- First Posted Date
- 2004-04-19
- Last Posted Date
- 2012-09-11
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00004252
- Locations
- πΊπΈ
Tower Hematology Oncology Medical Group, Los Angeles, California, United States
πΊπΈRaleigh Hematology/Oncology Associates - Wake Practice, Raleigh, North Carolina, United States
πΊπΈAPN-IMPATH Research Corporation, Fort Lee, New Jersey, United States
Study of the GARFT Inhibitor AG2037 in Patients With Metastatic Colorectal Cancer Who Failed Treatment
Phase 2
Completed
- Conditions
- Colorectal Neoplasms
- First Posted Date
- 2004-03-02
- Last Posted Date
- 2006-11-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 56
- Registration Number
- NCT00078468
- Locations
- πΊπΈ
Pfizer Investigational Site, New York, New York, United States
A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.
Phase 2
Completed
- Conditions
- Breast Neoplasms
- First Posted Date
- 2004-02-18
- Last Posted Date
- 2008-11-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 64
- Registration Number
- NCT00078000
- Locations
- πΊπΈ
Pfizer Investigational Site, Boston, Massachusetts, United States
Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.
Phase 2
Completed
- Conditions
- Colorectal Neoplasms
- First Posted Date
- 2004-02-18
- Last Posted Date
- 2007-01-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 84
- Registration Number
- NCT00077987
A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
Phase 2
Completed
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Drug: SU011248
- First Posted Date
- 2004-02-18
- Last Posted Date
- 2010-10-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 106
- Registration Number
- NCT00077974
- Locations
- πΊπΈ
Pfizer Investigational Site, Madison, Wisconsin, United States
AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer
Phase 1
Completed
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2004-01-14
- Last Posted Date
- 2012-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 174
- Registration Number
- NCT00076024
- Locations
- π¬π§
Pfizer Investigational Site, Sheffield, Yorkshire, United Kingdom
Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma
Phase 2
Completed
- Conditions
- Kidney Neoplasms
- First Posted Date
- 2004-01-14
- Last Posted Date
- 2012-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 52
- Registration Number
- NCT00076011
- Locations
- π©πͺ
Pfizer Investigational Site, Hannover, Germany
A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)
Phase 3
Completed
- Conditions
- Gastrointestinal Stromal Tumor
- Interventions
- Drug: PlaceboDrug: SU011248
- First Posted Date
- 2004-01-08
- Last Posted Date
- 2009-09-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 361
- Registration Number
- NCT00075218
- Locations
- π¬π§
Pfizer Investigational Site, Newcastle-Upon-Tyne, United Kingdom
A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy
Phase 1
Completed
- Conditions
- Lung Neoplasms
- First Posted Date
- 2003-12-24
- Last Posted Date
- 2006-11-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 87
- Registration Number
- NCT00074854
- Locations
- πΊπΈ
Pfizer Investigational Site, Smyrna, Tennessee, United States
Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer
Phase 2
Completed
- Conditions
- Ovarian NeoplasmsPeritoneal NeoplasmsFallopian Tube Neoplasms
- First Posted Date
- 2003-12-24
- Last Posted Date
- 2006-11-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 29
- Registration Number
- NCT00074867
- Locations
- π¨π¦
Pfizer Investigational Site, Quebec, Canada
Β© Copyright 2025. All Rights Reserved by MedPath